Great West Life Assurance Co. Can Acquires 1,312 Shares of Spark Therapeutics Inc (NASDAQ:ONCE)

Great West Life Assurance Co. Can grew its holdings in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 33.3% during the first quarter, HoldingsChannel.com reports. The firm owned 5,251 shares of the biotechnology company’s stock after purchasing an additional 1,312 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Spark Therapeutics were worth $596,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. State Board of Administration of Florida Retirement System increased its stake in Spark Therapeutics by 1.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 17,916 shares of the biotechnology company’s stock worth $2,040,000 after purchasing an additional 220 shares during the period. SG Americas Securities LLC increased its stake in Spark Therapeutics by 7.0% during the fourth quarter. SG Americas Securities LLC now owns 4,806 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 313 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in Spark Therapeutics by 10.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,117 shares of the biotechnology company’s stock worth $469,000 after purchasing an additional 399 shares during the period. Sterling Investment Advisors Ltd. purchased a new stake in Spark Therapeutics during the first quarter worth about $68,000. Finally, Mackay Shields LLC increased its stake in Spark Therapeutics by 5.4% during the fourth quarter. Mackay Shields LLC now owns 12,322 shares of the biotechnology company’s stock worth $482,000 after purchasing an additional 633 shares during the period. Institutional investors own 88.08% of the company’s stock.

ONCE stock opened at $97.70 on Friday. The company has a quick ratio of 5.59, a current ratio of 5.94 and a debt-to-equity ratio of 0.18. Spark Therapeutics Inc has a fifty-two week low of $34.53 and a fifty-two week high of $114.20.

ONCE has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Spark Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, February 23rd. William Blair began coverage on shares of Spark Therapeutics in a research note on Tuesday, February 26th. They set a “buy” rating on the stock. Sanford C. Bernstein lowered shares of Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $113.48 target price on the stock. in a research note on Tuesday, February 26th. Credit Suisse Group restated a “hold” rating and set a $47.00 target price on shares of Spark Therapeutics in a research note on Tuesday, February 19th. Finally, Stifel Nicolaus lowered shares of Spark Therapeutics from a “buy” rating to a “hold” rating and upped their target price for the stock from $65.00 to $114.50 in a research note on Wednesday, February 27th. One equities research analyst has rated the stock with a sell rating, seventeen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Spark Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $78.45.

ILLEGAL ACTIVITY WARNING: “Great West Life Assurance Co. Can Acquires 1,312 Shares of Spark Therapeutics Inc (NASDAQ:ONCE)” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/06/16/great-west-life-assurance-co-can-acquires-1312-shares-of-spark-therapeutics-inc-nasdaqonce.html.

Spark Therapeutics Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Featured Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.